Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilars Pricing In Medicare Part D Needs Legislative Fix, Avalere Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Requiring 50% discount for biosimilars in the coverage gap or establishing biosimilar specialty tier with reduced coinsurance could encourage broader take-up, consulting firm suggests.


Related Content

Biosimilars Ineligible For Reduced Medicaid Rebates As Authorized Generics


Related Companies